阿糖胞苷分别联合伊达比星、柔红霉素治疗急性非淋巴细胞白血病成本效果的比较分析

摘要

The purpose of this study is to compare the effect and cost of idarubicin combined with cy-tarabine (IA) or daunorubicin combined with cytarabine (DA) treatment in adult patients with acute non-lymphocytic leukemia, so as to tell which is more desirable considering cost and effect. A total of 102 cases of adult acute non-lymphocytic leukemia patients, given a course of IA or DA in 3+7 mode treat-ment, were analyzed for therapeutic efficacy and cost during hospitalization. The results showed that the complete remission rate and effective rate were higher in IA group than those in DA group (60.00% vs. 30.56%, 86.67% vs. 69.44%). Although the total cost of IA group was significantly higher than that of DA group (P<0.05), idarubicin is more effective and economic than daunorubicin when combined with cytara-bine, and it is worth promoting for use in clinic.%比较伊达比星联合阿糖胞苷（IA组）与柔红霉素联合阿糖胞苷（DA组）治疗成人急性非淋巴细胞白血病的效果、住院总费用并进行成本效果分析。选取了102例成人急性非淋巴细胞白血病患者，分别给予伊达比星联合阿糖胞苷和柔红霉素联合阿糖胞苷的一疗程（3+7）模式治疗，统计治疗效果和住院期间各项费用，结果IA组完全缓解率和有效率均高于DA组（60.00%vs.30.56%，86.67% vs.69.44%），虽然伊达比星的费用远高于柔红霉素，IA组患者住院总费用显著高于DA组（P<0.05），但成本效果分析显示IA方案优于DA方案，也就是说在与阿糖胞苷联用时，伊达比星与柔红霉素相比更为有效、经济，值得在临床上推广应用。